-
1
-
-
67650874081
-
Cancer statistics 2009
-
Jemal, A., Siegel, R., Ward, E. és mtsai: Cancer statistics 2009. CA Cancer J. Clin., 2009, 59, 225-249.
-
(2009)
CA Cancer J. Clin.
, vol.59
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
2
-
-
33644636306
-
A hazai és nemzetközi daganatos halálozási és megbetegedési mutatók alakulása. A népegészségügyi programok jellegzetességei és várható eredményei
-
Ottó Sz., Kásler M.: A hazai és nemzetközi daganatos halálozási és megbetegedési mutatók alakulása. A népegészségügyi programok jellegzetességei és várható eredményei. Magy. Onkol., 2005, 49, 99-107.
-
(2005)
Magy. Onkol.
, vol.49
, pp. 99-107
-
-
Ottó, Sz.1
Kásler, M.2
-
3
-
-
55049123815
-
Systemic therapy for metastatic renal cell carcinoma
-
Kroog, G. S., Motzer, R. J.: Systemic therapy for metastatic renal cell carcinoma. Urol. Clin. North Am., 2008, 35, 687-701.
-
(2008)
Urol. Clin. North Am.
, vol.35
, pp. 687-701
-
-
Kroog, G.S.1
Motzer, R.J.2
-
4
-
-
34250332941
-
Common and uncommon histologic subtypes of renal cell carcinoma: Imaging spectrum with pathologic correlation
-
Prasad, S. R., Humphrey, P. A., Catena, J. R. és mtsai: Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. RadioGraphics, 2006, 26, 1795-1810.
-
(2006)
RadioGraphics
, vol.26
, pp. 1795-1810
-
-
Prasad, S.R.1
Humphrey, P.A.2
Catena, J.R.3
-
5
-
-
0042821661
-
Chemotherapeutic strategies for renal cell carcinoma
-
Milowsky, M. I., Nanus, D. M.: Chemotherapeutic strategies for renal cell carcinoma. Urol. Clin. North Am., 2003, 30, 601-609.
-
(2003)
Urol. Clin. North Am.
, vol.30
, pp. 601-609
-
-
Milowsky, M.I.1
Nanus, D.M.2
-
6
-
-
0035134688
-
Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities
-
DOI 10.1634/theoncologist.6-1-34
-
Jonasch, E., Haluska, F. G.: Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist, 2001, 6, 34-55. (Pubitemid 32155814)
-
(2001)
Oncologist
, vol.6
, Issue.1
, pp. 34-55
-
-
Jonasch, E.1
Haluska, F.G.2
-
7
-
-
34248547900
-
A világossejtes veserák célzott terá piája és molekuláris patológiai alapjai
-
Tímár J., Kopper L., Bodrogi I.: A világossejtes veserák célzott terápiája és molekuláris patológiai alapjai. Magyar Onkológia, 2006, 50, 309-314.
-
(2006)
Magyar Onkológia
, vol.50
, pp. 309-314
-
-
Tímár, J.1
Kopper, L.2
Bodrogi, I.3
-
8
-
-
77953757715
-
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma
-
Schmidinger, M., Bellmunt, J.: Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat. Rev., 2010, 36, 416-424.
-
(2010)
Cancer Treat. Rev.
, vol.36
, pp. 416-424
-
-
Schmidinger, M.1
Bellmunt, J.2
-
9
-
-
0036138580
-
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
-
Motzer, R. J., Bacik, J., Murphy, B. A. és mtsai: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol., 2002, 20, 289-296.
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 289-296
-
-
Motzer, R.J.1
Bacik, J.2
Murphy, B.A.3
-
10
-
-
77954326508
-
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
On behalf of the ESMO Guidelines Working Group
-
Escudier, B., Kataja, V.: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. On behalf of the ESMO Guidelines Working Group. Ann. Oncol., 2010, 21 (Suppl. 5), v137-v139.
-
(2010)
Ann. Oncol.
, vol.21
, Issue.SUPPL. 5
-
-
Escudier, B.1
Kataja, V.2
-
11
-
-
79251574372
-
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
-
Patil, S., Figlin, R. A., Hutson, T. E. és mtsai: Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann. Oncol., 2011, 22, 295-300.
-
(2011)
Ann. Oncol.
, vol.22
, pp. 295-300
-
-
Patil, S.1
Figlin, R.A.2
Hutson, T.E.3
-
12
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
-
Motzer, R. J., Escudier, B., Oudard, S. és mtsai: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 2008, 372, 449-456.
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
13
-
-
1342288873
-
Expression of vascular endothelial growth factor protein in human renal cell carcinoma
-
Jacobsen, J., Grankvist, K., Rasmuson, T. és mtsai: Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int., 2004, 93, 297-302.
-
(2004)
BJU Int.
, vol.93
, pp. 297-302
-
-
Jacobsen, J.1
Grankvist, K.2
Rasmuson, T.3
-
14
-
-
11144354392
-
Direct evidence that the VEGF specific antibody bevacizumab has antivascular effects in human rectal cancer
-
Willett, C. G., Boucher, Y., di Tomaso, E. és mtsai: Direct evidence that the VEGF specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med., 2004, 10, 145-147.
-
(2004)
Nat. Med.
, vol.10
, pp. 145-147
-
-
Willett, C.G.1
Boucher, Y.2
Di Tomaso, E.3
-
15
-
-
77955880263
-
Emerging drugs for renal cell cancer
-
Varella, L., Rini, B. I.: Emerging drugs for renal cell cancer. Expert Opin. Emerg. Drugs, 2010, 15, 343-353.
-
(2010)
Expert Opin. Emerg. Drugs
, vol.15
, pp. 343-353
-
-
Varella, L.1
Rini, B.I.2
-
16
-
-
0042343801
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
-
Yang, J. C., Haworth, L., Sherry, R. M. és mtsai: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med., 2003, 349, 427-434.
-
(2003)
N. Engl. J. Med.
, vol.349
, pp. 427-434
-
-
Yang, J.C.1
Haworth, L.2
Sherry, R.M.3
-
17
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
-
DOI 10.1016/S0140-6736(07)61904-7, PII S0140673607619047
-
Escudier, B., Pluzanska, A., Koralewski, P. és mtsai: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet, 2007, 370, 2103-2111. (Pubitemid 350296300)
-
(2007)
Lancet
, vol.370
, Issue.9605
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
Ravaud, A.4
Bracarda, S.5
Szczylik, C.6
Chevreau, C.7
Filipek, M.8
Melichar, B.9
Bajetta, E.10
Gorbunova, V.11
Bay, J.-O.12
Bodrogi, I.13
Jagiello-Gruszfeld, A.14
Moore, N.15
-
18
-
-
43249085165
-
CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha monotherapy in metastatic renal cell carcinoma
-
Presented at Abstract 350
-
Rini, B., Halabi, S., Rosenberg, J. és mtsai: CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha monotherapy in metastatic renal cell carcinoma. Presented at Geni-tourinary Cancers Symposium, 2008, p. 267. Abstract 350.
-
Geni-tourinary Cancers Symposium, 2008
, pp. 267
-
-
Rini, B.1
Halabi, S.2
Rosenberg, J.3
-
19
-
-
0035990893
-
Protein kinases as targets for anticancer agents: From inhibitors to useful drugs
-
Fabbro, D., Ruetz, S., Buchdunger, E. és mtsai: Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther., 2002, 93, 79-98.
-
(2002)
Pharmacol. Ther.
, vol.93
, pp. 79-98
-
-
Fabbro, D.1
Ruetz, S.2
Buchdunger, E.3
-
20
-
-
33846148701
-
Sorafenib in advanced clear-cell renal cell carcinoma
-
Escudier, B., Eisen, T., Stadler, W. M. és mtsai: Sorafenib in advanced clear-cell renal cell carcinoma. N. Engl. J. Med., 2007, 356, 125-134.
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
21
-
-
77952207351
-
Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: Report of two cases and literature review
-
Kamada, P., Dudek, A. Z.: Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review. Cancer Invest., 2010, 28, 501-504.
-
(2010)
Cancer Invest.
, vol.28
, pp. 501-504
-
-
Kamada, P.1
Dudek, A.Z.2
-
22
-
-
62449186539
-
Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma
-
Escudier, B., Szczylik, C., Hutson, T. E. és mtsai: Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2009, 27, 1280-1289.
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 1280-1289
-
-
Escudier, B.1
Szczylik, C.2
Hutson, T.E.3
-
23
-
-
33644833910
-
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
-
Motzer, R. J., Michaelson, M. D., Redman, B. G. és mtsai: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2006, 24, 16-24.
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 16-24
-
-
Motzer, R.J.1
Michaelson, M.D.2
Redman, B.G.3
-
24
-
-
33744954585
-
Sunitinib in patients with metastatic renal cell carcinoma
-
DOI 10.1001/jama.295.21.2516
-
Motzer, R. J., Rini, B. I., Bukowski, R. M. és mtsai: Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 2006, 295, 2516-2524. (Pubitemid 43854967)
-
(2006)
Journal of the American Medical Association
, vol.295
, Issue.21
, pp. 2516-2524
-
-
Motzer, R.J.1
Rini, B.I.2
Bukowski, R.M.3
Curti, B.D.4
George, D.J.5
Hudes, G.R.6
Redman, B.G.7
Margolin, K.A.8
Merchan, J.R.9
Wilding, G.10
Ginsberg, M.S.11
Bacik, J.12
Kim, S.T.13
Baum, C.M.14
Michaelson, M.D.15
-
25
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer, R. J., Hutson, T. E., Tomczak, P. és mtsai: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 2007, 356, 115-124.
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
26
-
-
68949145218
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
-
Motzer, R. J., Hutson, T. E., Tomczak, P. és mtsai: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2009, 27, 3584-3590.
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
27
-
-
60849102835
-
Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma
-
Hutson, T. E.: Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma. Expert Rev. Anticancer Ther., 2008, 8, 1723-1731.
-
(2008)
Expert Rev. Anticancer Ther.
, vol.8
, pp. 1723-1731
-
-
Hutson, T.E.1
-
28
-
-
77949429364
-
Sunitinib for the management of advanced renal cell carcinoma
-
Escudier, B.: Sunitinib for the management of advanced renal cell carcinoma. Expert Rev. Anticancer Ther., 2010, 10, 305-317.
-
(2010)
Expert Rev. Anticancer Ther.
, vol.10
, pp. 305-317
-
-
Escudier, B.1
-
29
-
-
72549101585
-
Neoadjuvant treatment of renal cell carcinoma
-
Rathmell, W. K., Pruthi, R., Wallen, E.: Neoadjuvant treatment of renal cell carcinoma. Urol. Oncol., 2010, 28, 69-73.
-
(2010)
Urol. Oncol.
, vol.28
, pp. 69-73
-
-
Rathmell, W.K.1
Pruthi, R.2
Wallen, E.3
-
30
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
-
Sternberg, C. N., Davis, I. D., Mardiak, J. és mtsai: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J. Clin. Oncol., 2010, 28, 1061-1068.
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
-
31
-
-
79551584678
-
Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC): Final overall survival (OS) results
-
Abstract LBA22
-
Sternberg, C. N., Hawkins, R. E., Szczylik, C. és mtsai: Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC): final overall survival (OS) results. Ann. Oncol., 2010, 21 (Suppl. 8), Abstract LBA22.
-
(2010)
Ann. Oncol.
, vol.21
, Issue.SUPPL. 8
-
-
Sternberg, C.N.1
Hawkins, R.E.2
Szczylik, C.3
-
32
-
-
77958043734
-
Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
-
Goldstein, R., Pickering, L., Larkin, J.: Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? Expert Rev. Anticancer Ther., 2010, 10, 1545-1557.
-
(2010)
Expert Rev. Anticancer Ther.
, vol.10
, pp. 1545-1557
-
-
Goldstein, R.1
Pickering, L.2
Larkin, J.3
-
33
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes, G., Carducci, M., Tomczak, P. és mtsai: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med., 2007, 356, 2271-2281.
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
34
-
-
79953810848
-
Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC)
-
Abstr. 4608
-
Osanto, S., Hutson, T. E., Calvo, E. és mtsai: Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol., 2010, 28 (May 20 Suppl.), Abstr. 4608.
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.MAY 20 SUPPL.
-
-
Osanto, S.1
Hutson, T.E.2
Calvo, E.3
-
35
-
-
39649122843
-
A preeclampsia- like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
-
Patel, T. V., Morgan, J. A., Demetri, G. D. és mtsai: A preeclampsia- like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J. Natl. Cancer Inst., 2008, 100, 282-284.
-
(2008)
J. Natl. Cancer Inst.
, vol.100
, pp. 282-284
-
-
Patel, T.V.1
Morgan, J.A.2
Demetri, G.D.3
-
36
-
-
78649379884
-
How to select targeted therapy in renal cell cancer
-
Escudier, B., Albiges, L., Blesius, A. és mtsai: How to select targeted therapy in renal cell cancer. Ann. Oncol., 2010, 21 (Suppl. 7), vii59-vii62.
-
(2010)
Ann. Oncol.
, vol.21
, Issue.SUPPL. 7
-
-
Escudier, B.1
Albiges, L.2
Blesius, A.3
-
37
-
-
79953808494
-
Sequencing of therapeutic agents in the treatment of advanced renal cell carcinoma: Focus on mechanism of action
-
Oudard, S., Ravaud, A., Escudier, B.: Sequencing of therapeutic agents in the treatment of advanced renal cell carcinoma: Focus on mechanism of action. Annals of Urology, 2010, 10, 4.
-
(2010)
Annals of Urology
, vol.10
, pp. 4
-
-
Oudard, S.1
Ravaud, A.2
Escudier, B.3
|